Revenue during the quarter surged 32.28 percent to $7.18 million from $5.43 million in the previous year period. Gross margin for the quarter expanded 485 basis points over the previous year period to 70.57 percent. Operating margin for the quarter stood at negative 20.52 percent as compared to a negative 33.48 percent for the previous year period.

Operating loss for the quarter was $1.47 million, compared with an operating loss of $1.82 million in the previous year period.

Stavros Vizirgianakis, president and chief executive officer of Misonix, said, "We turned in a solid performance in the third quarter of fiscal 2017 driven by a 39% increase in domestic consumables sales and delivery of our initial stocking order to our new distributor in the People’s Republic of China. From a strategic standpoint, we firmly believe that our business in the United States offers the best opportunity for growth and we are focused on expanding consumables sales and driving recurring revenue in this market. To that end, we have expanded the number of Clinical Sales Specialists in our domestic sales and marketing group and the results to date have been excellent, as evidenced by the strong increase in domestic consumables sales in the third quarter."

Cash conversion cycle (CCC) has decreased to 95 days for the quarter from 271 days for the last year period. Days sales outstanding went down to 53 days for the quarter compared with 69 days for the same period last year.

Days inventory outstanding has decreased to 105 days for the quarter compared with 277 days for the previous year period. At the same time, days payable outstanding went down to 63 days for the quarter from 75 for the same period last year.